NCT06910657 2026-03-02
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Phase 1 Recruiting
Clinical Trials
10 trialsNCT07006077 2026-02-27
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Hangzhou Converd Co., Ltd.
Phase 2 Recruiting
NCT07001592 2025-06-03
RIOT3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT02562755 2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3 Completed
NCT01171651 2016-01-20
A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
SillaJen, Inc.
Phase 2 Completed
NCT01380600 2016-01-08
Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1 Completed
NCT00574977 2015-12-28
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Phase 1 Completed
NCT01387555 2015-03-11
TRAVERSE
Jennerex Biotherapeutics
Phase 2 Completed
NCT00629759 2013-01-04
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Jennerex Biotherapeutics
Phase 1 Completed